Brand Name(s):Arimidex

Indication: Cancer -breast (oestrogen-receptor positive in post-menopausal women)



Review Date:Apr-22

For patients under the care of DBTH FT, the specialist service will request a DEXA scan when aromatase inhibitors are started, and then write to the GP with the result and recommendation. Whilst the patient is still under DBTH FT followup (for 5 years post treatment) the service will arrange follow up DEXA scans and write to the GP with the result. This is managed by the Nurse Practitioner.
When patients are discharged, DBTH FT will write to the GP. If aromatase inhibtors are to be continued the service writes to the GP, asking the GP to take over care and informing the GP when the next DEXA scan is due. A date is also provided when the aromatase inhibitor is due to be stopped.
Written communication from Miss C.Rogers, Clinical Lead for Breast Surgery, DBTH FT

October 2018NICE CG164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Updated March 2017
NICE CG164 can be found at:
Issued: June 2013